DelveInsight’s ‘Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast–2034’ report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Key Takeaways from the Age-related Macular Degeneration Market Report
Discover which therapies are expected to grab the Age-related Macular Degeneration Market Share @ Age-related Macular Degeneration Market Outlook
Age-related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is a progressive eye condition that primarily affects the central part of the retina called the macula. The macula is responsible for providing sharp central vision, which is essential for activities such as reading, driving, and recognizing faces..
Age-related Macular Degeneration Epidemiology Insights
The epidemiology section of Age-related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Age-related Macular Degeneration Epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights
Age-related Macular Degeneration Market Insights
AMD is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss. People rarely lose all of their vision from age-related macular degeneration. Their central vision might be bad, but they’re still able to do many normal daily activities. Usually, patients are also able to still use their peripheral vision. The dry age-related macular degeneration (dAMD) tends to get worse slowly. There is no cure for macular degeneration. Treatment may slow it down or keep the loss of vision. A large number of studies found have shown, that people with dry AMD could slow the disease by taking supplements of vitamins C and E, lutein, zeaxanthin, zinc, and copper.
Age-related Macular Degeneration Treatment Landscape
The therapeutic landscape of dry AMD is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of dry AMD is poorly understood. However, there are chances of failure to reach the primary outcomes that might be linked to the advanced stage of the disease rather than a lack of action on appropriate targets. There is a significant unmet need for a therapy to decrease its progression. Dry AMD’s pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets.
To know more about Age-related Macular Degeneration treatment guidelines, visit @ Age-related Macular Degeneration Treatment Market Landscape
Age-related Macular Degeneration Drug Market
The overall market of Age-related Macular Degeneration (AMD) is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2023–2034).
Age-related Macular Degeneration Emerging Therapy Assessment
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Market key player, such as Opthea Limited, Kodiak Sciences Inc, Outlook Therapeutics, Inc., and others are developing drugs for the treatment of Wet-AMD, whereas, companies like Alkeus Pharmaceuticals, Iveric Bio, and others are developing drugs for the treatment of Dry-AMD.
Age-related Macular Degeneration Drugs Uptake
Age-related Macular Degeneration Companies
Several Age-related Macular Degeneration companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
Learn more about the FDA-approved drugs for Age-related Macular Degeneration @ Drugs for Age-related Macular Degeneration Treatment
Scope of the Age-related Macular Degeneration Market Report
Discover more about Age-related Macular Degeneration Drugs in development @ Age-related Macular Degeneration Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. Wet AMD Market Overview at a Glance
4. Dry AMD Market Overview at a Glance
5. Wet AMD Market: Future Perspective
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Drugs of Wet AMD
14. AMD: Seven Major Market Analysis
15. Key Opinion Leaders’ Views
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Market Access and Reimbursement of Wet AMD
20. Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/